The following table provides an overview of the latest patents of Arena Pharmaceuticals, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3860590Jun 7, 2023Methods For The Treatment Of Scleroderma2
EP3310760Oct 19, 2022Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders2